OTC Markets OTCQB - Delayed Quote USD

Hydreight Technologies Inc. (HYDTF)

2.2000 +0.0950 (+4.51%)

At close: November 9 at 4:00:00 PM EST

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

CNW Group 1mo ago

NURS.V

VST.CN

6F6.F
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

PR Newswire 1mo ago

NURS.V

VST.CN

6F6.F
Hydreight Technologies Inc (HYDTF) (Q2 2026) Earnings Call Highlights: Record Revenue Surges ...

GuruFocus.com 2mo ago

NURS.V

HYDTF
+4.51%
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

PR Newswire 2mo ago

NURS.V

SO6

NURS
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

CNW Group 2mo ago

NURS.V

NURS

SO6.F
Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A

PR Newswire 2mo ago

VSQTF

SO6.F

HYDTF
+4.51%
Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A

CNW Group 2mo ago

NURS.V

HYDTF
+4.51%
VSQTF
Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

PR Newswire 3mo ago

NURS.V

NURS.NE

HYDTF
+4.51%
Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

CNW Group 3mo ago

NURS.V

NURS.NE

HYDTF
+4.51%
Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

CNW Group 3mo ago

NURS.V

HYDTF
+4.51%
NURS.NE
Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

PR Newswire 3mo ago

HYDTF
+4.51%
NURS

SO6.F
Hydreight Announces Refiling of Interim Financial Statements

PR Newswire 5mo ago

NURS.V

SO6

HYDTF
+4.51%

U.S. markets open in 5h 25m

Hydreight Technologies Inc. (HYDTF)

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Hydreight Technologies Inc (HYDTF) (Q2 2026) Earnings Call Highlights: Record Revenue Surges ...

Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A

Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A

Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

Hydreight Announces Refiling of Interim Financial Statements